The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
|Videos|May 25, 2016
- Gastrointestinal Cancers: mCRC (Issue 8)
Novel Targets in Gastric Cancer
Author(s)Manish Shah, MD
Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell discusses novel targets in gastric cancer outside of HER2.
Advertisement
Articles in this issue
over 10 years ago
Pessimism Surrounds VEGF Inhibitors in Advanced Gastric Cancerover 10 years ago
Immunotherapies Provide Promising Results in Advanced Gastric Cancerover 10 years ago
The Link Between Helicobacter Pylori and Gastric Cancerover 10 years ago
Unmet Needs and Future Treatment Approaches in Gastric CancerAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5